3 Promising Penny Stocks With Market Caps Up To $900M

In the last week, the market has been flat, yet it is up 18% over the past year with earnings anticipated to grow by 17% per annum in the coming years. Penny stocks may be a throwback term, but they represent opportunities that are far from outdated. Typically associated with smaller or newer companies, these stocks can offer growth potential at lower price points when backed by strong financial health and solid fundamentals.

Let's take a closer look at a couple of our picks from the screened companies.

Akebia Therapeutics (AKBA)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutics for kidney disease patients, with a market cap of approximately $243.47 million.

Operations: The company's revenue of $219.06 million is derived from its focus on developing and commercializing innovative therapeutics.

Market Cap: $243.47M

Akebia Therapeutics, with a market cap of US$243.47 million, is navigating challenges typical of penny stocks. Despite being unprofitable and not expected to achieve profitability in the near term, Akebia has managed to maintain a cash runway exceeding three years due to positive free cash flow growth. Recent earnings showed a decline in revenue from US$62.47 million to US$49.13 million year-over-year for Q2 2026, with net losses reported at US$8.91 million compared to last year's net income of US$0.247 million. The company also initiated a Phase 2 trial for ebribafusp targeting rare kidney diseases, aiming for data release in 2027 amidst ongoing financial volatility and insider selling activities.

• Click here and access our complete financial health analysis report to understand the dynamics of Akebia Therapeutics.
• Assess Akebia Therapeutics' future earnings estimates with our detailed growth reports.

Chegg (CHGG)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Chegg, Inc. operates a learning platform that aids businesses in skill development and supports lifelong learners and students globally, with a market cap of approximately $93.72 million.

Operations: The company's revenue is primarily generated from its Educational Services segment, specifically in Education & Training Services, which amounts to $265.51 million.

Market Cap: $93.72M

Chegg, Inc., with a market cap of US$93.72 million, faces challenges typical of penny stocks. Despite having more cash than debt and sufficient short-term assets to cover liabilities, it remains unprofitable with losses increasing over the past five years. Recent earnings show a significant revenue drop from US$105.12 million to US$51.85 million year-over-year for Q2 2026, though net losses have narrowed considerably. The company is under pressure to regain NYSE compliance due to its share price falling below $1, potentially necessitating a reverse stock split while maintaining its listing amidst ongoing volatility and strategic buybacks.

• Dive into the specifics of Chegg here with our thorough balance sheet health report.
• Gain insights into Chegg's future direction by reviewing our growth report.

ATRenew (RERE)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: ATRenew Inc. operates in the People's Republic of China, selling pre-owned consumer electronics through online platforms and other channels, with a market cap of approximately $892.88 million.

Operations: The company's revenue is primarily generated from its retail electronics segment, amounting to CN¥24.17 billion.

Market Cap: $892.88M

ATRenew Inc., with a market cap of approximately $892.88 million, demonstrates significant growth potential as a penny stock. The company reported strong earnings growth of 130.6% over the past year, surpassing industry averages. Despite low Return on Equity at 11.9%, ATRenew maintains high-quality earnings and trades below its estimated fair value by 33.2%. Recent expansions include launching the ReRe Store in Hong Kong and developing international e-commerce platforms like FoneSquare, enhancing global reach in pre-owned electronics markets. Additionally, ATRenew's robust financial position is supported by more cash than debt and positive net income improvements year-over-year.

• Jump into the full analysis health report here for a deeper understanding of ATRenew.
• Learn about ATRenew's future growth trajectory here.

Seize The Opportunity

• Get an in-depth perspective on all 313 US Penny Stocks by using our screener here.
• Contemplating Other Strategies? The end of cancer? These 34 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com